If You Invested in Kadimastem (KMSTF)

KADIMASTEM LTD NEW (KMSTF) is associated with Kadimastem Ltd., a clinical-stage cell therapy company that has been progressing treatments in the biotechnology sector. According to multiple company announcements, Kadimastem has focused on the development and manufacturing of allogeneic, "off-the-shelf" cell products derived from human embryonic stem cells (hESCs) for serious chronic diseases, particularly neurodegenerative conditions and diabetes. The company has also been party to a merger transaction with NLS Pharmaceutics Ltd., under which their combined business is expected to operate as NewCelX Ltd. on the Nasdaq Capital Market under the ticker "NCEL."

Kadimastem is described in its disclosures as a clinical-stage cell therapy company developing allogeneic cell products based on a proprietary technology platform for the expansion and differentiation of hESCs into functional cells. Its work is situated within the broader field of biotechnology and research and development in cell-based therapies, aligning with the professional, scientific, and technical services sector.

Core therapeutic focus and pipeline

Company communications highlight two main product candidates:

• AstroRx®: an astrocyte cell therapy in clinical development for the treatment of amyotrophic lateral sclerosis (ALS), and also referenced as being in pre-clinical studies for other neurodegenerative indications.
• IsletRx: a program based on functional pancreatic islet-like cells that produce and release insulin and glucagon, intended to treat, and potentially cure, insulin-dependent diabetes. Company materials describe IsletRx as a scalable, stem cell–derived source of insulin-producing islet-like cells and note that it has been the subject of collaborations and patent protection efforts.

In several news releases, Kadimastem is further described as developing "off-the-shelf," allogeneic regenerative treatments for neurodegenerative diseases and diabetes, reinforcing its positioning within advanced cell therapy for high-need indications.

Technology platform

According to the company’s own descriptions, Kadimastem’s technology platform is designed for the expansion and differentiation of human embryonic stem cells into functional cells. This platform underpins both AstroRx® and IsletRx. The company has reported intellectual property developments, including patents related to cell selection and enrichment technology used in the IsletRx program, and has referenced patent coverage in multiple territories in connection with this diabetes-focused cell therapy.

Collaborations and programs mentioned in disclosures

Public communications reference collaborations and co-development activities around diabetes cell therapies. For example, Kadimastem has been described as working with iTolerance, Inc. on iTOL-102, a cell therapy targeting Type 1 diabetes that combines Kadimastem’s IsletRx technology with an immunomodulatory platform from iTolerance. Company statements also note support from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation for this co-development work, reflecting external interest in the scientific and clinical potential of these programs.

In addition, Kadimastem has reported progress on regulatory interactions and preparations for clinical development, including reference to a Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its diabetes program and plans for a Phase 2a clinical trial of AstroRx® for ALS. These references are presented by the company as part of its clinical development trajectory.

Corporate developments and merger with NLS Pharmaceutics

Recent news releases describe a significant corporate transformation involving a merger between NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd., and Kadimastem. The companies have announced that:

• The U.S. Securities and Exchange Commission declared effective a registration statement on Form F-4 related to the merger.
• All material conditions precedent to the completion of the merger have been fulfilled or waived by the parties.
• The closing of the merger has been set for October 30, 2025, with Kadimastem’s ordinary shares scheduled to be delisted from trading on the Tel Aviv Stock Exchange (TASE) on October 31, 2025.
• The combined company will be called NewCelX Ltd. and is expected to be listed on the Nasdaq Capital Market under the ticker symbol "NCEL".

These disclosures indicate that Kadimastem, historically traded on TASE under the symbol KDST, is being integrated into a new, Nasdaq-listed biotechnology entity. For investors looking at KMSTF, this context is important: the symbol reflects a company whose business has been the subject of a merger and delisting process as described in the company’s own announcements.

Industry classification and sector

Based on the provided classification, KADIMASTEM LTD NEW is associated with Research and Development in Biotechnology within the Professional, Scientific, and Technical Services sector. Company materials consistently describe Kadimastem as a clinical-stage biotechnology or cell therapy company, emphasizing its focus on cell-based therapies derived from hESCs for neurodegenerative diseases and diabetes.

Historical context and financing

Past news items describe financing rounds and strategic investments that have supported Kadimastem’s clinical and research programs. For example, a private financing round from ILEX Medical was reported as being earmarked to finance further clinical development of AstroRx® for ALS and to begin clinical development of IsletRx for insulin-dependent diabetes. Other communications mention broader fundraising efforts and strategic goals such as preparing for a Nasdaq listing, which later evolved into the merger structure with NLS Pharmaceutics.

Company statements also reference leadership and scientific origins, including the founding of Kadimastem by Professor Michel Revel, who is described as the company’s Chief Scientific Officer and a recipient of the Israel Prize for the invention and development of Rebif®, a multiple sclerosis therapy. This background is highlighted in the company’s own materials as part of its scientific heritage.

Status considerations for investors

For users researching KMSTF, it is important to note the explicit disclosures that Kadimastem’s ordinary shares on the Tel Aviv Stock Exchange are scheduled to be delisted upon completion of the merger, and that the combined company is expected to trade on Nasdaq under the new ticker NCEL. These statements come directly from joint press releases by NLS Pharmaceutics and Kadimastem. As a result, KMSTF should be viewed in the context of a company undergoing a corporate combination and transition to a new listed entity, rather than as a standalone, ongoing issuer under its historical structure.

Use of this overview

This overview summarizes information drawn from company press releases and public descriptions about Kadimastem’s business focus, therapeutic programs, technology platform, and merger-related developments. It is intended to provide structural context for understanding KMSTF and the underlying business history associated with Kadimastem Ltd., without making forward-looking assessments or investment recommendations.